文献速递免疫规划传染病防控与疫情报告

靶向未成熟树突状细胞的疟疾孢子体疫苗具有延长保护能力

Extended protection capabilities of an immature dendritic-cell targeting malaria sporozoite vaccine.
PubMed 文献 · Vaccine · 2017-03-23

研究在小鼠模型中评估一种新型蛋白疫苗构架:将未成熟树突状细胞靶向趋化因子MIP3α与恶性疟原虫环子孢子蛋白(CSP)融合,并联合佐剂聚肌胞苷酸(poly(I:C))。间隔三周两次接种可诱导极高的MIP3α依赖性抗体应答,末次免疫后第3周和第23周用表达恶性疟原虫CSP的转基因伯氏疟原虫孢子体攻击,两个时间点均观察到肝脏孢子体负荷减少97%。

要点

  • 间隔三周两次接种诱导极高的MIP3α依赖性抗体应答。
  • MIP3α靶向未成熟树突状细胞上的CCR6受体并显著增强接种部位细胞浸润。
  • 末次免疫后第3周和第23周攻击,肝脏孢子体负荷均减少97%。

核心结论

  • 该MIP3α融合CSP疫苗联合poly(I:C)在小鼠中诱导高水平抗体,并在末次免疫后第23周仍维持对肝脏孢子体负荷的97%减少。

研究设计与样本

  • 小鼠模型系统研究,评估MIP3α与恶性疟原虫CSP融合蛋白疫苗联合poly(I:C)佐剂的保护能力,间隔三周接种两次。

主要发现

  • 间隔三周两次接种诱导极高的MIP3α依赖性抗体应答。
  • MIP3α靶向未成熟树突状细胞上的CCR6受体并显著增强接种部位细胞浸润。
  • 末次免疫后第3周和第23周以静脉注射5×10³个表达恶性疟原虫CSP的转基因伯氏疟原虫孢子体攻击,两个时间点肝脏孢子体负荷均减少97%。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mouse studies evaluating candidate malaria vaccines have typically examined protective efficacy over the relatively short time frames of several weeks after the final of multiple immunizations. The current study examines the protective ability in a mouse model system of a novel protein vaccine construct in which the adjuvant polyinosinic polycytidilic acid (poly(I:C)) is used in combination with a vaccine in which the immature dendritic cell targeting chemokine, macrophage inflammatory protein 3 alpha (MIP3α), is fused to the circumsporozoite protein (CSP) of Plasmodium falciparum (P. falciparum). Two vaccinations, three weeks apart, elicited extraordinarily high, MIP3α-dependent antibody responses. MIP3α was able to target the vaccine to the CCR6 receptor found predominantly on immature dendritic cells and significantly enhanced the cellular influx at the vaccination site. At three and 23 weeks after the final of two immunizations, mice were challenged by intravenous injection of 5×103 transgenic Plasmodium berghei sporozoites expressing P. falciparum CSP, a challenge dose approximately one order of magnitude greater than that which is encountered after mosquito bite in the clinical setting. A ninety-seven percent reduction in liver sporozoite load was observed at both time points, 23 weeks being the last time point tested.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Luo K, Zavala F, Gordy J, et al. Extended protection capabilities of an immature dendritic-cell targeting malaria sporozoite vaccine. Vaccine. 2017. PMID: 28342669. doi:10.1016/j.vaccine.2017.03.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。